Vol. 233 Nos. 1–3 **April 20th 2007**

CONTENTS

Cited in: *Biological Abstracts; Elsevier BIOBASE/Current Awareness in Biological Sciences; Cambridge Scientific Abstracts; Chemical Abstracts; Current Contents/Life Sciences, EMBASE/Excerpta Medica; Environmental Mutagene Information Center; Environmental Periodicals Bibliography; Index Medicus; International Pharmaceutical Abstracts (IPA). Also covered in the abstract and citation database SCOPUS®. Full text available on ScienceDirect®.*

Special Issue:

Tenth International Medical Chemical Defence Conference (MCDC) 2006

"New Strategies in Medical Protection Against Organophosphorus Compounds"

Bundeswehr Medical Academy
Munich, Germany
26th to 27th April 2006

Guest Editors: Ladislaus Szinicz, Elsa Reiner and Peter Eyer
Co-Editor: Franz Worek

Editorial

Tenth International Medical Chemical Defence Conference 2006 "New strategies in medical protection against organophosphorus compounds"
L. Szinicz, E. Reiner, P. Eyer (Germany, Croatia) 1–2

Obituary

In memory of Ilse Hagedorn
P. Eyer (Germany) 3–7

Articles

Medical countermeasures to WMDs: Defence research for civilian and military use
M.G. Hamilton, P.M. Lundy (USA, Canada) 8–12

The dilemma of approving antidotes
C. Steffen (Germany) 13–19

Problems in the supply of antidotes—A view from the pharmaceutical industry
J. Ruprecht (Germany) 20–22

Development of antidotes: Problems and strategies
L. Szinicz, F. Worek, H. Thiermann, K. Kehe, S. Eckert, P. Eyer (Germany) 23–30

Stoichiometric and catalytic scavengers as protection against nerve agent toxicity: A mini review
D.E. Lenz, D. Yeung, J.R. Smith, R.E. Sweeney, L.A. Lumley, D.M. Cerasoli (USA) 31–39

Polyethylene-glycol conjugated recombinant human acetylcholinesterase serves as an efficacious bioscavenger against soman intoxication
C. Kronman, O. Cohen, L. Raveh, O. Mazor, A. Ordentlich, A. Shafferman (Israel) 40–46

Human paraoxonase: A promising approach for pre-treatment and therapy of organophosphorus poisoning
D. Rochu, E. Chabrière, P. Masson (France, Germany) 47–59

Sensitivity of butyrylcholinesterase knockout mice to (−)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission
E.G. Duysen, B. Li, S. Darvesh, O. Lockridge (Canada) 60–69

Acetylcholinesterase: Converting a vulnerable target to a template for antidotes and detection of inhibitor exposure
P. Taylor, Z. Kovarik, E. Reiner, Z. Radić (USA, Croatia) 70–78

Mutation of acetylcholinesterase to enhance oxime-assisted catalytic turnover of methylphosphonates
Z. Kovarik, Z. Radić, H.A. Berman, P. Taylor (USA, Croatia) 79–84

Evaluation of monoquaternary pyridinium oximes potency to reactivate tabun-inhibited human acetylcholinesterase
R. Odžak, M. Čalić, T. Hrenar, I. Primožič, Z. Kovarik (Croatia) 85–96
Adaptive changes in acetylcholinesterase gene expression as mediators of recovery from chemical and biological insults
T. Evron, D. Greenberg, T.S. Mor, H. Soreq (Israel, USA) 97–107
Testing of antidotes for organophosphorus compounds: Experimental procedures and clinical reality
P. Eyer, L. Szinicz, H. Thiermann, F. Worek, T. Zilker (Germany) 108–119
Development of next generation medical countermeasures to nerve agent poisoning
J. Wetherell, M. Price, H. Mumford, S. Armstrong, L. Scott (UK) 120–127
Swine models in the design of more effective medical countermeasures against organophosphorus poisoning
F. Dorandeu, J.R. Mikler, H. Thiermann, C. Tenn, C. Davidson, T.W. Sawyer, G. Lallement, F. Worek (France, Canada, Germany) 128–144
Lessons to be learnt from organophosphorus pesticide poisoning for the treatment of nerve agent poisoning
H. Thiermann, L. Szinicz, P. Eyer, N. Felgenhauer, T. Zilker, F. Worek (Germany) 145–154
Simulation of cholinesterase status at different scenarios of nerve agent exposure
F. Worek, P. Eyer, L. Szinicz, H. Thiermann (Germany) 155–165
Enzyme-kinetic investigation of different sarin analogues reacting with human acetylcholinesterase and butyrylcholinesterase
A. Bartling, F. Worek, L. Szinicz, H. Thiermann (Germany) 166–172
Evaluation of HI 6 treatment after percutaneous VR exposure by use of a kinetic-based dynamic computer model
N. Aurbek, H. Thiermann, L. Szinicz, F. Worek (Germany) 173–179
Reversible inhibition of acetylcholinesterase by carbamates or huperzine A increases residual activity of the enzyme upon soman challenge
S. Eckert, P. Eyer, F. Worek (Germany) 180–186
Asymmetric fluorogenic organophosphates for the development of active organophosphate hydrolases with reversed stereoselectivity
G. Amitai, R. Adani, G. Yacov, S. Yishay, S. Teitlboim, L. Tveria, O. Limanovich, M. Kushnir, H. Meshulam (Israel) 187–198
Cholinergic modulation of periaqueductal grey neurons: Does it contribute to epileptogenesis after organophosphorus nerve agent intoxication?
M. Sanada, F. Zheng, T. Huth, C. Alzheimer (Germany) 199–208
Reevaluation of indirect field stimulation technique to demonstrate oxime effectiveness in OP-poisoning in muscles in vitro
T. Seeger, F. Worek, L. Szinicz, H. Thiermann (Germany) 209–213
Anaesthesia in patients suffering from organophosphorus intoxication—interactions between general anaesthetics and acetylcholine in cortical networks in vitro
C. Grasshoff, H. Thiermann, B. Antkowiak (Germany) 214–222

Abstracts

Comparison of sulfur mustard induced mechanism of cell damage in dependency of time course and cell type
W. Bloch, A. Elischer, M. Schriek, K. Böhm, F. Moghbeli, K. Kehe, L. Szinicz, D. Steinritz (Germany) 223
Apoptotic effect of sarin on sarcoma L1 cells—In vitro study
R. Zdanowski, O. Antkowiak, T. Oldak, M. Brytan, M. Kowalczyk (Poland) 224
Cholinergic modulation of normal and epileptiform activity in cortico-striatal networks in vitro
B. Sutor (Germany) 224–225
Transcription factor NF-κB as mediator of sulfur mustard induced damage of the skin
B. Rebholz, K. Kehe, R.A. Rupec (Germany) 225
Do we need an extended use of 2-PAM in a severe organophosphate intoxication?
H.K. Roh, W.H. Um, J.S. Kim (Korea) 225–226
Functional states, storage and thermal stability of human paraoxonase: Drawbacks, advantages and potential
D. Rochu, F. Renault, M. Elias, S. Hanne, C. Cléry-Barraud, E. Chabrière, P. Masson (France, Germany) 226
Analysis of matrix metalloproteinase expression in different types of skin and lung cells after exposure to sulfur mustard
T. Popp, V. Egea, K. Kehe, M. Jochum, C. Ries (Germany) 227
Synthesis of glucoconjugates with heterocyclic oximes
R. Odžak, M. Oršulić, S. Tomić (Croatia) 227–228
Electrical detection of AChE activity using cell free electrophysiology
P. Obrdlik, A. Knecht, I. Janausch, B. Kelety (Germany) 228
Do oximes enhance the spontaneous reactivation of pyridostigmine inhibited acetylcholinesterase in the presence of soman inhibition?
Y.P. Lue, W.K. Loke (Singapore) 228–229
Atropine degradation products and trace heavy metal content in AtroPen® and ComboPen® auto-injectors
M. Loch, T. Zimmermann (Germany) 229–230
Two aging pathways for organophosphorus-inhibited human butyrylcholinesterase resolved by MALDI-TOF mass spectrometry
H. Li, F. Nachon, L.M. Schopfer, P. Masson, O. Lockridge (USA, France) 230
Nanoparticulate systems for brain delivery of oximes: First loading studies
J. Kufleitner, J. Hermanns, H. von Briesen, J. Kreuter (Germany) 230–231
Potency of new structurally different oximes to reactivate cyclosarin inhibited-human brain acetylcholinesterases
K. Kuca, J. Cabal, D. Jun, J. Bajgar, J. Kassa, J. Fusek (Czech Republic) 231–232

Synthesis of new pyridinium oximes and evaluation of their potency to reactivate tabun-phosphorylated acetylcholinesterase
Z. Kovarik, R. Odžak, M. Čalić, S. Tomic (Croatia) 232
The effect of atropine dosage on the efficacy of other pretreatment and treatment medical countermeasures for nerve agent intoxication
I. Koplovitz, S. Schulz, R. Railer, M. Sigler, C. Kelleher, M. Shutz (USA) 232–233
Development of a rapid and reliable on-site sulfur mustard detector
S. Klaus, C. Beitsch, M. Scheibenzuber (Germany) 233
Development of a human co-culture model of a bronchial unit *in vitro* to investigate toxic pathomechanisms
M.I. Hermanns, F. Bittinger, M. Bock, S. Fuchs, C.J. Kirkpatrick (Germany) 233–234
Effects of sulfur mustard on fibroblast and keratinocyte co-cultures
K. Kehe, J. Schneider, J. Emmler, H. Kreppel, M. Abend, L. Szinicz (Germany) 234–235
Phosphotriesterase modified by poly[*N*-(2-hydroxypropyl)methacrylamide]
D. Jun, K. Kuca, J. Bajgar, M. Hruby, J. Kucka, F. Renault, P. Masson (Czech Republic, France) 235
Effect of antioxidants on sulfur mustard-induced toxicity in an *in vitro*-model of the human blood–air barrier
J. Emmler, M.I. Hermanns, H. Kreppel, K. Kehe, L. Szinicz (Germany) 235–236
Novel hybrid acetylcholinesterase inhibitors: Synthesis, docking and inhibition studies
P.W. Elsinghorst, M. Gütschow (Germany) 236
Towards optimization of high-throughput methods for assessing genotoxic damage by carcinogenic chemicals or ionizing radiation
M. Debiak, M. Moreno-Villanueva, T. Sindlinger, A. Bürkle (Germany) 237
In vitro interactions between pyridinium aldoximes and endogenous bio-scavenger butyrylcholinesterase in tabun poisoning
M. Čalić, Z. Kovarik (Croatia) 237–238
Species specific binding constants of atropine to muscarinic receptors
R. Bogan, H. Thiermann, L. Szinicz (Germany) 238
Functional quality testing of Bundeswehr autoinjectors: AtroPen®, ComboPen® and morphine autoinjectors
T. Zimmermann, K. Eggert-Bury (Germany) 238–239

Addendum

Development of physiologically based toxicokinetic and toxicodynamic models for nerve agents
J.P. Langenberg, H.C. Trap, M.J. Van der Schans (The Netherlands) 240